West Names New President of Pharmaceutical Packaging Systems
News Oct 10, 2014
West Pharmaceutical Services, Inc. has appointed Karen Flynn President of the company's Pharmaceutical Packaging Systems business. Pharmaceutical Packaging Systems is a global business unit within West, and is the company's largest, generating annual sales revenue of nearly $1 billion.
"Karen has a strong track record of growing revenue, while maintaining high team engagement and motivation, and has been incredibly successful in the management of our Americas business," said Donald E. Morel, Jr., Chairman and Chief Executive Officer, West. "As West enters a very exciting period of anticipated growth, the Board and I are confident in Karen's ability to serve as one of our company's key business leaders."
Karen Flynn brings more than 28 years of experience to this role. Most recently, she held the position of President, Americas Region, Pharmaceutical Packaging Systems, where she was responsible for the Americas regional business segment, including both the manufacturing and commercial aspects of the business.
From 2000 to 2008, Flynn was a part of Catalent (formerly known as a division of Cardinal Health), where she worked in Sales Management, finishing her career there as Vice President, Global Accounts. Prior to Catalent, Flynn spent 15 years at West, in roles spanning Quality, R&D, Technical Services and Sales. In 2008, she rejoined West as Vice President, Sales, Americas.
Flynn holds a Bachelor of Science in Pre-Professional Studies (Pre-Med) from The University of Notre Dame, a Master of Science in Business Administration from Boston University, and a Master of Science in Engineering from The University of Pennsylvania. She is a member of the Healthcare Businesswomen's Association, the Forum of Executive Women, and serves on the Downingtown STEM Academy Advisory Board.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE